OBJECTIVE: To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, and patient-reported outcomes. METHODS: This multi-national, non-interventional, cross-sectional study (NCT01981473) enrolled adult patients with RA treated continuously for 6-24 months with ETN, ADL, or IFX. ADA and trough drug concentrations were measured by independent assays ≤2 days before the next scheduled dose. Efficacy measurements included Disease Activity Score 28-joint count (DAS28), low disease activity (LDA), remission, and erythrocyte sedimentation rate (ESR). Targeted medical histories of injection site/infusion reactions, serum sickness, and thromboembolic events were collected. RESULTS: Baseline demographics of the 595 patients (ETN: n = 200; ADL: n = 199; IFX: n = 196) were similar across groups. The mean duration of treatment was 14.6, 13.5, and 13.1 months for ETN, ADL, and IFX, respectively. All ETN-treated patients tested negative for ADA, whereas 31.2% and 17.4% patients treated with ADL and IFX, respectively, tested positive. In ADL- or IFX-treated patients, those with ADA had significantly lower trough drug concentrations. There were negative correlations between trough drug levels and both CRP and ESR in ADL- and IFX-treated patients. DAS28-ESR LDA and remission rates were higher in patients without ADA. The rate of targeted medical events reported was low. CONCLUSION: ADA were detected in ADL- and IFX-treated but not ETN-treated patients. Patients without ADA generally showed numerically better clinical outcomes than those with ADA. TRIAL REGISTRATION: This study was registered on www.ClinicalTrials.gov (NCT01981473).
OBJECTIVE: To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, and patient-reported outcomes. METHODS: This multi-national, non-interventional, cross-sectional study (NCT01981473) enrolled adult patients with RA treated continuously for 6-24 months with ETN, ADL, or IFX. ADA and trough drug concentrations were measured by independent assays ≤2 days before the next scheduled dose. Efficacy measurements included Disease Activity Score 28-joint count (DAS28), low disease activity (LDA), remission, and erythrocyte sedimentation rate (ESR). Targeted medical histories of injection site/infusion reactions, serum sickness, and thromboembolic events were collected. RESULTS: Baseline demographics of the 595 patients (ETN: n = 200; ADL: n = 199; IFX: n = 196) were similar across groups. The mean duration of treatment was 14.6, 13.5, and 13.1 months for ETN, ADL, and IFX, respectively. All ETN-treated patients tested negative for ADA, whereas 31.2% and 17.4% patients treated with ADL and IFX, respectively, tested positive. In ADL- or IFX-treated patients, those with ADA had significantly lower trough drug concentrations. There were negative correlations between trough drug levels and both CRP and ESR in ADL- and IFX-treated patients. DAS28-ESR LDA and remission rates were higher in patients without ADA. The rate of targeted medical events reported was low. CONCLUSION:ADA were detected in ADL- and IFX-treated but not ETN-treated patients. Patients without ADA generally showed numerically better clinical outcomes than those with ADA. TRIAL REGISTRATION: This study was registered on www.ClinicalTrials.gov (NCT01981473).
Authors: Geertje M Bartelds; Charlotte L M Krieckaert; Michael T Nurmohamed; Pauline A van Schouwenburg; Willem F Lems; Jos W R Twisk; Ben A C Dijkmans; Lucien Aarden; Gerrit Jan Wolbink Journal: JAMA Date: 2011-04-13 Impact factor: 56.272
Authors: Stef P Menting; Paula P M van Lümig; Anna-Christa Q de Vries; Juul M P A van den Reek; Desiree van der Kleij; Elke M G J de Jong; Phyllis I Spuls; Lidian L A Lecluse Journal: JAMA Dermatol Date: 2014-02 Impact factor: 10.282
Authors: L A Korswagen; G M Bartelds; C L M Krieckaert; F Turkstra; M T Nurmohamed; D van Schaardenburg; C A Wijbrandts; P P Tak; W F Lems; B A C Dijkmans; R M van Vugt; G J Wolbink Journal: Arthritis Rheum Date: 2011-04
Authors: M K de Vries; I E van der Horst-Bruinsma; M T Nurmohamed; L A Aarden; S O Stapel; M J L Peters; J C van Denderen; B A C Dijkmans; G J Wolbink Journal: Ann Rheum Dis Date: 2008-03-28 Impact factor: 19.103
Authors: Fabien B Vincent; Eric F Morand; Kim Murphy; Fabienne Mackay; Xavier Mariette; Christian Marcelli Journal: Ann Rheum Dis Date: 2012-11-24 Impact factor: 19.103
Authors: R K Dore; S Mathews; J Schechtman; W Surbeck; D Mandel; A Patel; L Zhou; P Peloso Journal: Clin Exp Rheumatol Date: 2007 Jan-Feb Impact factor: 4.473
Authors: Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman Journal: Pediatrics Date: 2019-05-02 Impact factor: 7.124
Authors: Silvia Sirotti; Elena Generali; Angela Ceribelli; Natasa Isailovic; Maria De Santis; Carlo Selmi Journal: Auto Immun Highlights Date: 2017-07-12
Authors: Robert J Moots; Ricardo M Xavier; Chi Chiu Mok; Mahboob U Rahman; Wen-Chan Tsai; Mustafa H Al-Maini; Karel Pavelka; Ehab Mahgoub; Sameer Kotak; Joan Korth-Bradley; Ron Pedersen; Linda Mele; Qi Shen; Bonnie Vlahos Journal: PLoS One Date: 2017-06-05 Impact factor: 3.240
Authors: Qiang Shi; Ko-Jen Li; Tamas Treuer; Bruce C M Wang; Carol L Gaich; Chien-Hsun Lee; Wen-Shuo Wu; Wesley Furnback; Chao-Hsiun Tang Journal: PLoS One Date: 2018-04-06 Impact factor: 3.240